GlassScriptPhysician profile
Timothy Vaughn Sandell
NPI 1679522254
$3,031.79
in general payments reported to CMS, 2019-2025
23 companies · $1,179 in 2025
The $1,179 reported for 2025 was more than what 76% of Pain Medicine (Physical Medicine & Rehabilitation) providers received nationally (typical 2025 total: $400).
See the full distribution for Pain Medicine (Physical Medicine & Rehabilitation)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.49 · 2023: $287 · 2024: $1,552 · 2025: $1,179.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,018.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,018.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $466.97 | 2024-2025 | Proclaim, Eterna |
| Boston Scientific Corporation | $383.32 | 2023-2025 | Intracept, General - Pain Management |
| Abbvie INC. | $344.89 | 2023-2025 | Botox, Ubrelvy |
| Saluda Medical Americas, INC. | $309.08 | 2024-2025 | Evoke |
| Pfizer INC. | $241.94 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $201.04 | 2023-2025 | Relistor |
| Tersera Therapeutics LLC | $191.04 | 2024-2025 | Prialt |
| Medtronic, INC. | $173.91 | 2024-2025 | Inceptiv, Intellis Adaptivestim |
| Lundbeck LLC | $99.81 | 2024-2025 | Vyepti |
| Collegium Pharmaceutical, INC. | $93.22 | 2023-2025 | Xtampza |
| Averitas Pharma INC. | $87.50 | 2024-2025 | Qutenza |
| Merz Pharmaceuticals, LLC | $79.76 | 2025 | Xeomin |
| Scilex Pharmaceuticals INC. | $71.88 | 2023-2025 | Ztlido |
| Nevro Corp. | $58.73 | 2024 | Senza |
| Globus Medical, INC. | $43.82 | 2025 | Senza |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ibsa Pharma INC. | $37.28 | 2024-2025 | Tirosint, Licart, Flector |
| Idorsia Pharmaceuticals US INC | $34.02 | 2023 | Quviviq |
| Tonix Medicines, INC. | $27.41 | 2025 | Tonmya |
| Spinal Simplicity, LLC | $24.28 | 2024 | Ha Minuteman G3-R |
| Bioventus LLC | $20.75 | 2024 | Durolane |
| Vertex Pharmaceuticals Incorporated | $16.88 | 2025 | |
| Sentynl Therapeutics, INC. | $13.49 | 2019 | |
| Sonex Health, INC. | $10.77 | 2023 | Sx-One Microknife |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Sandell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.